Do you want to read an article? Please log in or register.
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
Parkinson’s Disease
Related content
Anxiety and Depression
Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial
Lancet Neurol.
Lhommée E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, Timmermann L, Hälbig TD, Pineau F, Durif F, Witjas T, Pinsker M, Mehdorn M, Sixel-Döring F, Kupsch A, Krüger R, Elben S, Chabardès S, Thobois S, Brefel-Courbon C, Ory-Magne F, Regis JM, Maltête D, Sauvaget A, Rau J, Schnitzler A, Schüpbach M, Schade-Brittinger C, Deuschl G, Houeto JL, Krack P; EARLYSTIM study group
doi: 10.1016/
RECOMMENDED
Parkinson’s Disease
Diagnosis and Treatment of Parkinson Disease: A Review
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
JAMA.
Armstrong MJ, Okun MS
doi: 10.1001/jama.2019.22360.
Aging and Cognitive Functions
Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial
JAMA Neurol.
Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC
doi: 10.1001/
Parkinson’s Disease
Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease: A Systematic Review and Meta-analysis
JAMA Netw Open.
Artusi CA, Dwivedi AK, Romagnolo A, Pal G, Kauffman M, Mata I, Patel D, Vizcarra JA, Duker A, Marsili L, Cheeran B, Woo D, Contarino MF, Verhagen L, Lopiano L, Espay AJ, Fasano A, Merola A
doi: 10.1001/jamanetworkopen.
Parkinson’s Disease
Is Parkinson's disease a chronic low-grade inflammatory bowel disease?
J Neurol.
Rolli-Derkinderen M, Leclair-Visonneau L, Bourreille A, Coron E, Neunlist M, Derkinderen P
doi: 10.1007/s00415-
Parkinson’s Disease
Rasagiline and safinamide as a dopamine-sparing therapy for parkinson's disease
Acta Neurol Scand.
Avila A, Caballol N, Martín-Baranera M, Gómez-Ruiz I, Balagué-Marmaña M, Planas-Ballvé A, Cardona X
doi: 10.1111/ane.
COMMENTED
Multiple Sclerosis
Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases
Read the related editorial recommended by Dr med. Andreas Hottinger:
Parkinson Disease and Autoimmune Disorders-What Can We Learn From Genome-wide Pleiotropy?
doi: 10.1001/
Multiple Sclerosis
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, MSBase Study Group
doi: 10.1001/jama.
Aging and Cognitive FunctionsDementia
Initial cognitive changes in Parkinson's disease
Mov Disord.
Weintraub D, Tröster AI, Marras C, Stebbins G
doi: 10.1002/mds.27330.